Kahn Brothers Group Q1 2026 13F Holdings and Activity Report

I. Institutional Overview

A deep dive into the institutional structure reveals a firm that remains steadfast in its commitment to a concentrated, high-conviction strategy. With only 47 distinct holdings, Kahn Brothers Group does not seek to mirror the broader market indices. Instead, it operates with a deliberate focus, where the top positions exert a disproportionate influence on the overall performance. This concentration—where a handful of stocks represent the lion's share of the capital—suggests an institutional psychology that is comfortable with idiosyncratic risk in exchange for the potential of significant long-term outperformance. In an era often dominated by passive indexing and high-frequency algorithmic trading, the firm’s approach is a testament to the enduring relevance of fundamental, bottom-up research.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

II. Sector Allocation Analysis

The most striking feature of this allocation is the overwhelming concentration in the top three sectors: Healthcare, Financials, and Communication Services. Together, these three sectors account for a staggering 80% of the total portfolio value. This level of concentration indicates a "highly focused" investment philosophy. Kahn Brothers is not betting on the "market"; they are betting on a specific set of economic outcomes. The heavy weighting in Healthcare (30.27%) and Financials (29.68%) suggests a dual-track strategy. On one hand, Healthcare provides a defensive, non-cyclical cushion with long-term growth tailwinds from an aging global population. On the other hand, the massive commitment to Financials reflects a bet on interest rate environments and the intrinsic value of large-scale banking and insurance institutions.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

III. Top 10 Holdings Deep Dive

Citigroup remains the undisputed heavyweight in the Kahn Brothers portfolio, representing nearly 17% of the total assets. This is a classic "conviction holding." Despite a slight reduction in the number of shares held (down 4.04%), the position's dominance is unshaken. The investment logic here is likely centered on the massive multi-year restructuring led by the bank's management. For a value investor like Kahn, Citigroup represents a "sum-of-the-parts" play where the market has historically undervalued its global footprint and institutional services business. The slight reduction this quarter should not be viewed as a loss of faith but rather as a tactical rebalancing to manage the extreme concentration risk that a 17% position naturally entails. The fact that the portfolio weight remains so high despite the share reduction suggests that Citigroup's price performance has been relatively resilient compared to other holdings.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

IV. Major Buys/Additions

The most significant addition this quarter was to Organon & Co., where the firm increased its position by over 52%. Organon, a spinoff from Merck, focuses on women's health, biosimilars, and established brands. From a value perspective, Organon is a classic "unloved spinoff." These entities often face initial selling pressure from institutional investors who received shares but don't want to hold a smaller, specialized company. Kahn Brothers is leaning into this dislocation. The motivation here is likely "growth acceleration bet" combined with "valuation trough mining." Organon trades at a significant discount to the broader healthcare sector, yet it possesses a stable of cash-generating legacy products and a promising pipeline in women's health. By committing an estimated $11.45 million in additional capital, Kahn is signaling that the "mission" for Organon is just beginning.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

V. Major Sells and Exits

The massive 47.15% reduction in Merck is the most significant cash-out event of the quarter, recouping an estimated $24.34 million. Merck has been a long-term winner for many value investors, driven by the success of its oncology blockbuster, Keytruda. However, with the "patent cliff" for Keytruda approaching later this decade, Kahn Brothers appears to be making a "strategic retreat." This is a "high amount + high weight" operation. The logic is clear: lock in gains while the valuation is still robust and reallocate that capital into Organon—the very company Merck spun off. This "sell the parent, buy the child" strategy suggests Kahn believes the better value now lies in the specialized spinoff rather than the diversified parent.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

VI. Investment Insights and Risk Warnings

The logic chain is clear: 1. Harvest the Mature : Sell down positions where the valuation is full and the future growth (like the Keytruda tail) is well-understood. 2. Exit the Euphoria : Completely abandon high-flying tech (NVIDIA) to preserve the margin of safety. 3. Attack the Dislocation : Use the proceeds to buy into sectors facing temporary headwinds but possessing long-term structural dominance (Zillow in real estate) or specialized cash flows (Organon). 4. Maintain the Anchor : Keep the core foundation in deeply undervalued, restructuring financials (Citigroup).

For retail investors, the reference value here is not to blindly copy the Zillow or Organon buys, but to understand the discipline of capital recycling . Kahn Brothers demonstrates that a successful long-term strategy requires the courage to sell what is working to buy what is currently hated. Their move into Zillow, in particular, serves as a powerful reminder that value can often be found in "growth" companies that have been discarded by the market during cyclical downturns.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

Sources and limitations

This report uses public U.S. Securities and Exchange Commission Form 13F disclosures and structured data maintained by 13F Hub. A 13F filing is a quarter-end snapshot of reportable long positions, is normally published with a delay, and does not disclose every short position, cash balance, bond, derivative, or non-U.S. asset.

Narrative content is prepared from the same-period SEC disclosure and 13F Hub structured data, then checked before publication. This material is for research and education, not personalized investment advice.